每年專案
個人檔案
學歷
- 國防醫學院醫學院醫學士
經歷
- 2022.11- 臺北癌症中心院長
- 2022.11- 臺北醫學大學癌症轉譯研究中心主任
- 2022.04- 泰福生技股份有限公司獨立董事
- 2020.11- Distinguished Investigator and Director of Institute of Biotechnology and Pharmaceutical Research, NHRI
- 2020.08 Distinguished Investigator and Attending Physician of National Institute of Cancer Research, NHRI
- 2020.08 Professor Emeritus, National Cheng Kung University
- 2019.02-2020.07 Executive Vice President, National Cheng Kung University
- 2019.02-2020.07 Director of University Center for Bioscience and biotechnology, NCKU
- 2019.01-2020.12 教育部醫學教育會 委員
- 2015.01-2016.12 教育部醫學教育會 委員
- 2014.08-2019.07 Distinguished Professor and Dean, College of Medicine, National Cheng Kung University
- 2013.08-2014.07 Professor and Dean, College of Medicine, National Cheng Kung University
- 2008.09-2018.05 Distinguished Investigator of National Institute of Cancer Research, NHRI
- 2008.01-2013.07 Director of National Institute of Cancer Research, NHRI
- 2007.08- Attending Physician of Division of hematology/Oncology, NCKUH
- 2007.08-2013.07 Joined Professor, College of Medicine, National Cheng Kung University
- 2006.01-2007.12 Deputy Director of National Institute of Cancer Research, NHRI
- 2004.06-2008 Chairman of Safety and Data Monitoring committee, TCOG
- 2004.04-2008.08 Investigator of NHRI
- 2003.08-2007.07 Adjunct Professor of Internal Medicine, NDMC (部定，教字013198)
- 2003-2005 常務理事，Chinese Oncology Society
- 2001~ Board member of Chinese Oncology Society
- 2000.09-2004.03 Associate investigator of NHRI
- 1999 ~ Board member of Sino-American Cancer Foundation
- 1997-2006 Adjunct Attending physician of Department of Oncology, NTUH
- 1997- Senior Attending physician of NHRI
- 1997-2001 General Secretary of Chinese Oncology Society
- 1997 Chief of Hematology / Oncology, Cheng-Hsien Medical
Center - 1994-2003.07 Associate Professor of internal medicine, NDMC (部定，副字 21234)
- 1994-1996 Board member of Chinese BMT Society
- 1993-1996 Chief of Medical Oncology, Tri-Service General Hospital, National Defense Medical Center
- 1991-1992 Attending physician of Medical Mission in Republic of Central Africa
- 1989-1991 Visiting Scholar of Yale Medical School, Department of Pharmacology
- 1987-1989 Fellow of Medical Oncology Training Program of Institute of Biomedical Science, Academia Sinica
- 1987-1996 Attending Physician of Hematology / Oncology, Tri-Service General Hospital, NDMC
- 1986-1987 Chief resident of Division of Hematology / Oncology,
Department of Internal Medicine, TSGH, NDMC - 1982-1986 Resident of Department of Medicine, TSGH, NDMC
- 1981-1982 Internship training, Tri-Service General Hospital
研究興趣
- Development of anticancer drugs
- Study the mechanisms of anticancer drug resistance
指紋
查看啟用 Jang-Yang Chang 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
- 1 類似的個人檔案
網路
國家/地區層面的近期外部共同作業。按一下圓點深入探索詳細資料，或
專案
- 2 使用中
-
腫瘤微環境中癌細胞與免疫因子的串擾：頭頸癌的組織蛋白酶S相關調節機制鑑定和治療策略－溶酶體半胱氨酸蛋白酶組織蛋白酶S在頭頸癌腫瘤免疫中的作用：聚焦對IL-7的調節角色和潛在的免疫調節機制(2/3)
8/1/22 → 7/31/23
研究計畫: A - 政府部門 › b - 科技部
-
-
Discovery of Potential Neuroprotective Agents against Paclitaxel-Induced Peripheral Neuropathy
Chen, Y. F., Wu, C. H., Chen, L. H., Lee, H. W., Lee, J. C., Yeh, T. K., Chang, J. Y., Chou, M. C., Wu, H. L., Lai, Y. P., Song, J. S., Yeh, K. C., Chen, C. T., Lee, C. J., Shia, K. S. & Shen, M. R., 3月 24 2022, 於: Journal of Medicinal Chemistry. 65, 6, p. 4767-4782 16 p.研究成果: 雜誌貢獻 › 文章 › 同行評審
開啟存取1 引文 斯高帕斯（Scopus） -
Lon upregulation contributes to cisplatin resistance by triggering NCLX-mediated mitochondrial Ca2+ release in cancer cells
Tangeda, V., Lo, Y. K., Babuharisankar, A. P., Chou, H. Y., Kuo, C. L., Kao, Y. H., Lee, A. Y. L. & Chang, J. Y., 3月 2022, 於: Cell Death and Disease. 13, 3, 241.研究成果: 雜誌貢獻 › 文章 › 同行評審
開啟存取5 引文 斯高帕斯（Scopus） -
The Synergistic Inhibition of Coronavirus Replication and Induced Cytokine Production by Ciclesonide and the Tylophorine-Based Compound Dbq33b
Lee, Y. Z., Hsu, H. Y., Yang, C. W., Lin, Y. L., Chang, S. Y., Yang, R. B., Liang, J. J., Chao, T. L., Liao, C. C., Kao, H. C., Chang, J. Y., Sytwu, H. K., Chen, C. T. & Lee, S. J., 7月 2022, 於: Pharmaceutics. 14, 7, 1511.研究成果: 雜誌貢獻 › 文章 › 同行評審
開啟存取1 引文 斯高帕斯（Scopus） -
A novel NRF2/ARE inhibitor gossypol induces cytotoxicity and sensitizes chemotherapy responses in chemo-refractory cancer cells
Tang, Y. C., Chang, H. H., Chen, H. H., Yao, J. Y., Chen, Y. T., Chuang, Y. J., Chang, J. Y. & Kuo, C. C., 2021, 於: Journal of Food and Drug Analysis. 29, 4, 7.研究成果: 雜誌貢獻 › 文章 › 同行評審
開啟存取1 引文 斯高帕斯（Scopus） -
c-MYC-directed NRF2 drives malignant progression of head and neck cancer via glucose-6-phosphate dehydrogenase and transketolase activation
Tang, Y. C., Hsiao, J. R., Jiang, S. S., Chang, J. Y., Chu, P. Y., Liu, K. J., Fang, H. L., Lin, L. M., Chen, H. H., Huang, Y. W., Chen, Y. T., Tsai, F. Y., Lin, S. F., Chuang, Y. J. & Kuo, C. C., 3月 11 2021, 於: Theranostics. 11, 11, p. 5232-5247 16 p.研究成果: 雜誌貢獻 › 文章 › 同行評審
開啟存取34 引文 斯高帕斯（Scopus）
資料集
-
Novel microtubule inhibitor MPT0B098 inhibits hypoxia-induced epithelial-to-mesenchymal transition in head and neck squamous cell carcinoma
Tsai, I. (Contributor), Kuo, C. (Contributor), Liou, J. (Creator) & Chang, J. (Contributor), Figshare, 2018
DOI: 10.6084/m9.figshare.c.4052207.v1, https://figshare.com/collections/Novel_microtubule_inhibitor_MPT0B098_inhibits_hypoxia-induced_epithelial-to-mesenchymal_transition_in_head_and_neck_squamous_cell_carcinoma/4052207/1
資料集: Dataset